A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer. READ MORE

Conferences

Patients with early-stage breast cancer often undergo advanced imaging tests despite recommendations against doing so. 

READ MORE

News

By Megan Brooks

NEW YORK (Reuters Health) - Omitting radiation after lumpectomy for pure ductal carcinoma in situ (DCIS) does not improve the chance of breast preservation in case of local recurrence, researchers from Canada have observed.

READ MORE

A recent comparative effectiveness study examined long-term survival outcomes for patients with breast cancer after undergoing either mastectomy or breast-conserving surgery.

READ MORE

Researchers examined the decision-making processes of patients with breast cancer to understand why a procedure that does not improve survival is increasingly being considered.

READ MORE

Research in Review

A bone metastasis model has been created that simulates interactions between metastatic breast cancer cells and bone cells to determine effectiveness of different treatments.

READ MORE

Adding palbociclib to fulvestrant prolongs progression-free survival compared with fulvestrant alone among pre- and post-menopausal women with HR-positive/HER2-negative metastatic breast cancer.

READ MORE

Using body composition metrics to determine dosage of anthracyclines-taxane based chemotherapy for patients with breast cancer can reduce treatment-related toxicity, according to a study published in Clinical Cancer Research.

READ MORE

Women with breast cancer are more likely to discontinue chemoprevention therapy if menopause-specific symptoms negatively impact their quality of life (QOL), according to a study published in the Journal of Clinical Oncology (February 2017;35[6]:629-635).

READ MORE